Nimotuzumab Phase III start marks oncology progress for Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Enrolment has begun in two pivotal Phase III Asian clinical trials for nimotuzumab (DE-766), building the foundation for the possible approval of the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody in gastric and lung cancer.